Author

Gweneth Levy 1

1 AbbVie Inc., North Chicago, United States

BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione, Irina Blumenstein, Peter Irving, Ramona Vladea, Dapo Ilo, Wen Zhou, Gweneth Levy, Xuan Yao, Iris Dotan

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D.R. Higgins, Edward V. Loftus Jr., Severine Vermeire

Item 1 - 2 / 2
1